Pharmaceutical companies that use AI to discover and develop drugs will likely be exempt from the need to comply with new regulatory requirements introduced under the European Commission’s AI Act, which is set to enter into force within the next two months.
Instead, the European Medicines Agency (EMA) will be in charge of overseeing the safe use of AI in drug development, according
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?